Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a synthetic small molecule belonging to the class of phenylpyrroles and indole derivatives. It has been studied as an experimental agent, primarily for its activity as an inverse agonist or antagonist at the steroid hormone receptor ERRα (Estrogen-related receptor alpha, also known as ERR1). The compound has not been approved for any medical use and remains in preclinical or early-stage research. Its mechanism involves modulation of nuclear hormone receptors, which are implicated in metabolic regulation and potentially relevant to conditions such as gestational diabetes mellitus (GDM) and other metabolic disorders. No clinical trials or approved indications are reported for this molecule[2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-cyclohexyl-N-{[1-(4-methylphenyl)-1H-indol-3-yl]methyl}methanamine.